ea0098c6 | Clinical – Chemo/SSA/Biologics | NANETS2023
Mohamed A.
, Kurian M.
, Patil S.
, Asa S.L.
, Tirumani S.H.
, Mahipal A.
, Bajor D.
, Chakrabarti S.
, Selfridge J.E.
, Ocuin L.M.
, Hoehn R.S.
, Winter J.
, Ammori J.
, Hardacre J.
, Henke L.E.
, Bahar L.
Background: Somatostatin analogues (SSAs) are the standard of care first line therapy for metastatic well-differentiated neuroendocrine tumors (NETs). They are approved for both alleviating hormone-related symptoms for functional tumors and inhibiting tumor growth. Their anti-proliferative benefit in the refractory setting is debatable due to lack of supportive literature. This systematic review compared efficacy of targeted therapies (Everolimus, Sunitinib, Surufatinib, Lenva...